Evaluation of the Ion AmpliSeq SARS-CoV-2 Research Panel by Massive Parallel Sequencing
Authors:
- Federica AlessandriniFAFederica Alessandrini
- Sara CaucciSCSara Caucci
- Valerio OnofriVOValerio Onofri
- Filomena MelchiondaFMFilomena Melchionda
- Adriano TagliabracciAdriano Tagliabracci
- Patrizia BagnarelliPBPatrizia Bagnarelli
- Laura Di SanteLSLaura Di Sante
- Chiara TurchiCTChiara Turchi
- Stefano MenzoStefano Menzo
Open Access
Abstract
Deep knowledge of the genetic features of SARS-CoV-2 is essential to track the ongoing pandemic through different geographical areas and to design and develop early diagnostic procedures, therapeutic strategies, public health interventions, and vaccines. We describe protocols and first results of the Ion AmpliSeq™ SARS-CoV-2 Research Panel by a massively parallel sequencing (MPS) assay. The panel allows for targeted sequencing by overlapping amplicons, thereby providing specific, accurate, and high throughput analysis. A modified reverse transcription reaction, which consists of the use of a SARS-CoV-2 specific primers pool from the Ion AmpliSeq SARS-CoV-2 Research Panel, was assessed in order to promote viral RNA specific reverse transcription. The aim of this study was to evaluate the effectiveness of the Ion AmpliSeq™ SARS-CoV-2 Research Panel in sequencing the entire viral genome in different samples. SARS-CoV-2 sequence data were obtained from ten viral isolates and one nasopharyngeal swab from different patients. The ten isolate samples amplified with 12 PCR cycles displayed high mean depth values compared to those of the two isolates amplified with 20 PCR cycles. High mean depth values were also obtained for the nasopharyngeal swab processed by use of a target-specific reverse transcription. The relative depth of coverage (rDoC) analysis showed that when 12 PCR cycles were used, all target regions were amplified with high sequencing coverage, while in libraries amplified at 20 cycles, a poor uniformity of amplification, with absent or low coverage of many target regions, was observed. Our results show that the Ion AmpliSeq SARS-CoV-2 Research Panel can achieve rapid and high throughput SARS-CoV-2 whole genome sequencing from 10 ng of DNA-free viral RNA from isolates and from 1 ng of DNA-free viral RNA from a nasopharyngeal swab using 12 PCR cycles for library amplification. The modified RT-PCR protocol yielded superior results on the nasopharyngeal swab compared to the reverse transcription reaction set up according to the manufacturer’s instructions.Keywords
This publication has 15 references indexed in Scilit:
- SARS-CoV-2 Phylogenetic Analysis, Lazio Region, Italy, February–March 2020Emerging Infectious Diseases, 2020
- Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in ItalyClinical Microbiology and Infection, 2020
- Phylogenetic pattern of SARS-CoV-2 from COVID-19 patients from Bosnia and Herzegovina: lessons learned to optimize future molecular and epidemiological approachesbioRxiv, 2020
- High-density amplicon sequencing identifies community spread and ongoing evolution of SARS-CoV-2 in the Southern United StatesbioRxiv, 2020
- Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern ItalyJournal of Virology, 2020
- Isolation and rapid sharing of the 2019 novel coronavirus ( SARS ‐CoV‐2) from the first patient diagnosed with COVID ‐19 in AustraliaMedical Journal of Australia, 2020
- Genomic characterization and phylogenetic analysis of SARS‐COV‐2 in ItalyJournal of Medical Virology, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- The Origin of SARS-CoV-2 in Istanbul: Sequencing findings from Epicenter of Pandemic in TurkeyNorthern Clinics of Istanbul, 2020
- Integrative genomics viewerNature Biotechnology, 2011